Sarcopedia

BenignBone

Benign Fibrous Histiocytoma

Synonyms: BFH, fibrous histiocytoma of Bone

Diagnosis of exclusion - must rule out Malignant Fibrous histiocytoma and other Fibrous lesions

Quick Facts

Behaviour

Benign

Category

Bone

Synonyms

  • BFH
  • fibrous histiocytoma of Bone

Category

Bone

Behaviour

Benign

Gender

M = F

Tissue of Origin

Fibrous

Epidemiology

  • Rare tumour accounting for <1% of primary Bone tumours
  • Wide age range but peak incidence in 2nd–4th decades

Clinical Features

  • Usually presents with pain and swelling
  • May be asymptomatic and incidentally discovered
  • Rarely causes pathological fracture

Location

  • Femur most common
  • Tibia
  • Pelvis and flat bones occasionally

Imaging

  • Geographic lytic lesion with well-defined sclerotic margins
  • No periosteal reaction in most cases
  • May show cortical thinning or expansion
  • No matrix mineralisation

Pathology

  • Storiform pattern of spindle cells
  • Histiocyte-like cells and giant cells present
  • Foamy macrophages frequently seen
  • Low mitotic activity

Genetics

  • No recurrent cytogenetic abnormalities identified
  • Polyclonal lesion in most cases

Treatment

  • Curettage with or without Bone grafting
  • Extended curettage with adjuvants (phenol, liquid nitrogen) for recurrent lesions
  • Wide excision reserved for aggressive or recurrent cases

Prognosis

  • Excellent prognosis after complete excision
  • Local recurrence rate approximately 10–20%
  • Malignant transformation exceedingly rare

Key Points

  • Diagnosis of exclusion - must rule out Malignant Fibrous histiocytoma and other Fibrous lesions
  • Histologically identical to soft tissue counterpart
  • Close follow-up recommended due to recurrence risk

Workup - Blood Tests

FBC, U&E, LFTs, Bone profile - pre-operative baseline

Workup - Local Imaging

  • Plain radiograph - geographic lytic lesion with well-defined sclerotic margins
  • MRI primary site - characterise lesion and exclude Malignant features
  • CT - cortical integrity assessment

Workup - Biopsy

Core needle biopsy or excision biopsy - diagnosis of exclusion

Workup - Staging

No staging required

Workup - Other

MDT discussion - extensive IHC panel required to confirm diagnosis of exclusion

Follow-up Summary

  1. 1

    Post-op visit within 6 weeks; plain X-ray at 6 weeks to confirm healing

  2. 2

    Year 1

    6-monthly clinical review with plain X-ray to detect early local recurrence

  3. 3

    Year 2

    Annual clinical review; plain X-ray if symptoms return

  4. 4

    Discharge at 2 years if no evidence of recurrence

  5. 5

    No CT or MRI routinely required unless recurrence suspected

  6. 6

    Recurrence (10–20%) should prompt repeat imaging (MRI) and MDT discussion

Medical disclaimer

The content on Sarcopedia is for educational and informational purposes only and does not constitute medical advice. It is not intended to be a substitute for professional medical diagnosis or treatment. Always consult with a qualified physician regarding any health concerns or before starting any new treatment. Reliance on any information provided on this site is solely at your own risk.